The effect of Rosvastatin on steatosis and fibrosis in patients with non-alcoholic fatty liver disease
Phase 3
- Conditions
- onalcoholic fatty liver disease (NAFLD).Fatty (change of) liver, not elsewhere classified
- Registration Number
- IRCT2017060212789N14
- Lead Sponsor
- Vice Chancellor for Research of Kurdistan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Main Inclusion Criteria: Non diabetics patients; normal FBS; BS2hpp;Hb1AC; Age 20 years and older; approved non fatty liver diagnosed by fibroscan; LFT(AST and ALT); rejection of other causes of fatty liver disease such as hepatitis B and C .
Main
Exclusion Criteria
Patients who have other liver diseases; contraindication for Rosvastatin; not taking hypoglycemic drugs such as metformin.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Steatosis of liver. Timepoint: Before intervention, six month after intervention. Method of measurement: Fibroscan.;Fibrosis of liver. Timepoint: Before intervention, six month after intervention. Method of measurement: Fibroscan.
- Secondary Outcome Measures
Name Time Method ALT. Timepoint: Before intervention, six month after intervention. Method of measurement: Blood examination.;AST. Timepoint: Before intervention, six month after intervention. Method of measurement: Blood examination.;LDL. Timepoint: Before intervention, six month after intervention. Method of measurement: Blood examination.;HDL. Timepoint: Before intervention, six month after intervention. Method of measurement: Blood examination.;Triglyceride. Timepoint: Before intervention, six month after intervention. Method of measurement: Blood examination.;Bilirubin. Timepoint: Before intervention, six month after intervention. Method of measurement: Blood examination.;Blood urea. Timepoint: Before intervention, six month after intervention. Method of measurement: Blood examination.;Blood creatinine. Timepoint: Before intervention, six month after intervention. Method of measurement: Blood examination.